Thank you, Seth. The September 30, 2017, we had cash and cash equivalents of approximately $4.2 million, as compared to approximately $3.6 million at December 31, 2016. The $0.6 million increase in cash and cash equivalents resulted from the sale of approximately $4.4 million of common stock during the nine months ended September 30, 2017, partially offset by net cash used in operating activities of approximately $3.6 million, and cash used in investing activities of approximately $0.2 million. We used cash during the nine months ended September 30, 2017, primarily to fund our general and administrative expenses and for research and development. We had approximately $3.6 million in working capital at September 30, 2017 as compared to working capital of approximately $3.4 million at December 31, 2016. Stockholders’ equity at September 30, 2017 was approximately $5.5 million compared to stockholders’ equity of approximately $5.6 million at December 31, 2016. For the third quarter ended September 30, 2017, net loss attributable to common shareholders was approximately $1.8 million, or a loss of $0.16 per share. In the same quarter of 2016, the net loss attributable to common shareholders was $2.1 million, or loss of $0.44 per share. Revenues were not significant in the quarter’s ended September 30, 2017 or 2016, as we have shifted our focus from our consulting business to our nuclear fuel. Stock-based compensation expense was $0.6 million for the nine months ended September 30, 2017 compared to $0.9 million for the nine months ended September 30, 2016. For the nine months ended September 30, 2017, the Company’s cash flows used in operating activities were $3.6 million versus $3.9 million used in operating activities for the same period of 2016. The cash was used primarily to fund general and administrative expenses and for research and development. I will be available for your questions during the next segment of today’s presentation. With that, back to you.